Prostate Cell News Volume 3.07 | Feb 24 2012

LABORATORY RESEARCH

Telomerase Reactivation following Telomere Dysfunction Yields Murine Prostate Tumors with Bone Metastases
To determine the role of telomere dysfunction and telomerase reactivation in generating pro-oncogenic genomic events and in carcinoma progression, an inducible telomerase reverse transcriptase allele was crossed onto a prostate cancer-prone mouse model null for Pten and p53 tumor suppressors. [Cell]
Abstract | Press Release

Adult Murine Prostate Basal and Luminal Cells Are Self-Sustained Lineages that Can Both Serve as Targets for Prostate Cancer Initiation
Using a lineage-tracing approach, researchers show that adult rodent prostate basal and luminal cells are independently self-sustained in vivo. [Cancer Cell] Abstract

Pten Loss and RAS/MAPK Activation Cooperate to Promote Epithelial-to-Mesenchymal Transition and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells
Researchers’ findings indicate that activation of RAS/MAPK signaling serves as a potentiating second hit to alteration of the PTEN/PI3K/AKT axis and co-targeting both pathways is highly effective in preventing the development of metastatic prostate cancers. [Cancer Res] Abstract

Increased Expression of NuSAP in Recurrent Prostate Cancer Is Mediated by E2F1
To characterize the role and regulation of NuSAP in prostate cancer, researchers studied the expression of NuSAP in the LNCaP and PC3 human prostate cancer cell lines. [Oncogene] Abstract

CCN3 Increases Cell Motility and ICAM-1 Expression in Prostate Cancer Cells
Here, researchers show that nephroblastoma overexpressed (CCN3) increased cell migration and intercellular adhesion molecule-1 (ICAM-1) expression in prostate cancer cells. In addition, expression of CCN3 was positively correlated with both cell migration and ICAM-1 expression in human prostate cancer cells. [Carcinogenesis] Abstract

miR-21 as an Independent Biochemical Recurrence Predictor and Potential Therapeutic Target for Prostate Cancer
Researchers evaluated the microRNA miR-21 as a biomarker to predict the risk of biochemical failure, and as a potential drug target for prostate cancer therapy. [J Urol] Abstract

Combining Growth Hormone-Releasing Hormone Antagonist with Luteinizing Hormone-Releasing Hormone Antagonist Greatly Augments Benign Prostatic Hyperplasia Shrinkage
Researchers investigated the influence of a combination of antagonists of growth hormone-releasing hormone and luteinizing hormone-releasing hormone on animal models of benign prostatic hyperplasia. [J Urol] Abstract

CLINICAL RESEARCH

Improved Clinical Outcomes with High-Dose Image Guided Radiotherapy Compared with Non-IGRT for the Treatment of Clinically Localized Prostate Cancer
The purpose of this study was to compare toxicity profiles and biochemical tumor control outcomes between patients treated with high-dose image-guided radiotherapy (IGRT) and high-dose intensity-modulated radiotherapy for clinically localized prostate cancer. [Int J Radiat Oncol Biol Phys] Abstract

Survival among Men with Clinically Localized Prostate Cancer Treated with Radical Prostatectomy or Radiation Therapy in the Prostate Specific Antigen Era
Radical prostatectomy, external beam radiotherapy and brachytherapy are accepted treatments for localized prostate cancer. In this study, researchers analyzed the survival of patients treated with these modalities according to contemporary standards. [J Urol] Abstract

The Results of Real-Time Brachytherapy for the Management of Low- and Intermediate-Risk Prostate Cancer in Patients with Prostate Volumes up to 100 mL
The objective of this study was to report the results of real-time brachytherapy in the management of low-risk and intermediate-risk prostate cancer in patients with prostate volumes up to 100 mL, over a six-year period. [BJU Int] Abstract

GTx Announces Clinical Hold on Clinical Trials Evaluating Capesaris® for First and Second Line Treatments of Advanced Prostate Cancer
GTx, Inc. announced that the U.S. Food and Drug Administration notified the company in a telephone call that the agency has placed a clinical hold on the company’s clinical trials evaluating Capesaris^® for first line androgen deprivation therapy for advanced prostate cancer and second line hormonal treatment. [GTx, Inc.] Press Release

Oncolytics Biotech® Inc. Enters into Sponsorship Agreement with NCIC CTG for Randomized Phase II Study in Prostate Cancer
Oncolytics Biotech Inc. announced that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen’s University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN® in patients with recurrent or metastatic castration resistant prostate cancer. [Oncolytics Biotech Inc.] Press Release

OICR Funds Prostate Cancer Study to Identify Aggressive vs. Non-Aggressive Disease
Deputy Director and Chief Scientific Officer of the Ontario Institute for Cancer Research (OICR) announced the launch of an innovative Phase III clinical trial that aims to determine whether multi-parametric magnetic resonance imaging coupled with transrectal ultrasound guided biopsy can accurately identify men with prostate cancer who are at risk of developing aggressive disease. [Ontario Institute for Cancer Research] Press Release

Nearing a Goal of 100 Young Investigators, the Prostate Cancer Foundation Expands Global Research Enterprise
A nearly $3.4 million investment raises the total of Prostate Cancer Foundation Young Investigators to 89. Young Investigator awards are designed to promote long-term careers in the field of prostate cancer by providing three year grants for transformational research focused on prostate cancer treatments to improve patient outcomes. [Prostate Cancer Foundation] Press Release

Molecular Insight Pharmaceuticals, Inc. Elects a New Board of Directors
Molecular Insight Pharmaceuticals, Inc. announced that it has elected a new Board of Directors. The new Board will support the Company’s strategic focus on the discovery, development, and commercialization of radiopharmaceuticals for molecular imaging and targeted radiotherapy of prostate cancer. [Molecular Insight Pharmaceuticals, Inc.] Press Release

NEW American Urological Association (AUA) Annual Meeting
May 19-23, 2012
Atlanta, United States

Visit our events page to see a complete list of events in the prostate cell community.

Scientist – Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientific Marketing Communications Specialist (STEMCELL Technologies, Inc.)

Research Technologist (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software, Inc.)

PhD Position – Cell Biology/Infection Research (University of Münster)

Clinical Research Associate (Jennerex Biotherapeutics, Inc.)

Research Associate – Development (Precision Therapeutics, Inc.)

Postdoctoral Research Fellow – Epidemiology / Prostate Studies (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow (Louisiana State University Health Sciences Center) 

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Middle East to Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.